Endoscopy 2020; 52(03): 193-201
DOI: 10.1055/a-1024-3967
Original article
© Georg Thieme Verlag KG Stuttgart · New York

A novel cryoballoon ablation system for eradication of dysplastic Barrett’s esophagus: a first-in-human feasibility study

Sanne Noortje van Munster*
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
2   Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, the Netherlands
,
Anouk Overwater*
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, the Netherlands
,
Mihaela G. M. Raicu
4   Pathology DNA, St. Antonius Hospital, Nieuwegein, the Netherlands
,
Kees C. A. Seldenrijk
4   Pathology DNA, St. Antonius Hospital, Nieuwegein, the Netherlands
,
Wouter B. Nagengast
5   Department of Gastroenterology and Hepatology, University Medical Center Groningen, the Netherlands
,
Erik J. Schoon
6   Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, the Netherlands
,
Jacques J. G. H. M. Bergman
2   Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, the Netherlands
,
Bas L. A. M. Weusten
1   Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, the Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 27. Mai 2019

accepted after revision 10. September 2019

Publikationsdatum:
11. November 2019 (online)

Preview

Abstract

Background Endoscopic cryoablation for Barrett’s esophagus (BE) might offer advantages over heat-based ablation. Focal cryoballoon ablation has been promising for short-segment BE, whereas the novel 90°-swipe cryoballoon ablation system (CbSAS90) ablates larger areas in a single step (90° over 3 cm). The system allows for dose adjustment. CbSAS90 has been feasible and safe in animal and pre-esophagectomy studies. This is the first clinical study to assess feasibility, safety, and efficacy of CbSAS90 for eradication of dysplastic BE.

Methods In this prospective study in dysplastic BE patients, dose finding started with semi-circumferential treatment at 0.8 mm/s (dose 1). The dose was escalated by reducing speed by 0.1 mm/s in six patients until BE surface regression was ≥ 80 % without complications (“effective dose”). The effective dose was subsequently confirmed with circumferential treatment in 12 new patients. Post-procedural pain (0 – 10) and dysphagia (0 – 4) were evaluated. Outcomes were feasibility, safety, and BE surface regression.

Results 25 patients were included, with technically successful treatment in 92 % (95 %CI 73 % – 99 %). Median (95 %CI) BE surface regression was 78 % (50 % – 85 %) for dose 1 and 85 % (55 % – 95 %) for dose 2 (0.7 mm/s), which was defined as the effective dose. Circumferential treatment resulted in 93 % (88 % – 96 %) regression. Two of 12 patients with circumferential treatment developed strictures that required dilation. Median pain and dysphagia scores were low (0 – 3 and 0, respectively).

Conclusions CbSAS90 was feasible and effective for ablating larger BE areas. The optimal dose for circumferential treatment that balances safety and efficacy requires further evaluation.

* These authors contributed equally to this work.


Fig. 1s